Skip to main content
Equibles
ONCO logo

ONCO · Onconetix, Inc. · Metrics

Track ONCO — free

Use ONCO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ONCO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.66 -0.07 (-10.03%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the unaudited condensed consolidated financial statements, which is not alleviated by management's plans.”
View the 10-Q filed Aug 13, 2026
Market Cap
$4.07M
Shares
3.95M
Volume · Oct 5 503.26K Avg daily vol (3M) 2.27M

ONCO metrics

52 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.73
Market cap
$4.07M

Price action

20 metrics
Price change (1W)
-28.8%
Price change (30D)
-12.7%
Price change (3M)
-23.3%
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
151.2%
Annualized volatility (3M)
168.1%
Beta
—
RSI (14D)
46.8
Price vs SMA 50
-5.9%
Price vs SMA 200
—
Avg volume (3M)
2.27M
Relative volume
0.2
Average dollar volume
$2.21M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
3.95M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 219,985.0%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
6.3×
reciprocal yield 15.9%
P / book
0.3
reciprocal yield 331.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-250.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
80.4%
Operating margin
-2,525.0%
Trailing 12 months
Net margin
-1,578.8%
Gross profit (TTM)
$519,226
Operating profit (TTM)
−$16.31M
Net income (TTM)
−$10.20M
Trailing 12 months
Diluted EPS (TTM)
$1,614.03
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$25,265.44

Growth

11 metrics
Revenue growth YoY
-83.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$645,824
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+19,654.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-75.7%
Return on assets
-62.1%
Debt / equity
—
Current ratio
2.2
EBITDA (TTM)
−$16.29M
Free cash flow (TTM)
—
Quick ratio
2.1
Interest coverage
-52.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$5.94M
Latest balance sheet
Cash & equivalents
$5.94M
Total assets
$16.43M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$10.31M
Capital expenditures (TTM)
$28,471
R&D (TTM)
$129,850
SG&A (TTM)
$8.13M
Stock compensation (TTM)
$43,693
R&D / revenue
—
Stock compensation / revenue
6.8%

Ownership (13F)

3 metrics
13F filers
6
13F filer change QoQ
+1
Institutional ownership
1.7%

Short interest

3 metrics
Short interest
3.4%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1782107 CUSIP 68237Q401 Visit website Investor relations